NanoViricides (NNVC) News Today → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free NNVC Stock Alerts $2.40 -0.03 (-1.23%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 8:48 AM | finance.yahoo.comA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and MoreMay 29 at 8:38 AM | proactiveinvestors.comNanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicinesMay 25, 2024 | americanbankingnews.comNanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.comMay 23, 2024 | proactiveinvestors.comNanoViricides taps Aagami to seek out licensing and partnership opportunitiesMay 23, 2024 | finance.yahoo.comNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.May 21, 2024 | proactiveinvestors.comNanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believeMay 20, 2024 | finanznachrichten.deNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20, 2024 | proactiveinvestors.comNanoViricides reports strong antiviral activity of NV-387 against RSVMay 19, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo FinanceMay 14, 2024 | proactiveinvestors.comNanoViricides unveils new data showing lead drug asset's strong activity against RSVMay 14, 2024 | finance.yahoo.comA Novel Broad-Spectrum Antiviral with Activity Against RSVMay 13, 2024 | proactiveinvestors.comNanoViricides CEO discusses NV-387's broad-spectrum antiviral potentialMay 10, 2024 | proactiveinvestors.comNanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global ConferenceMay 10, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York CityMay 8, 2024 | proactiveinvestors.comNanoViricides says lead asset shows antiviral activity against Smallpox and MpoxMay 8, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/MpoxMay 8, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC)May 6, 2024 | ca.investing.comNanoViricides drug asset shows ‘superior antiviral effects’ against Influenza AMay 6, 2024 | msn.comNanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare moversMay 6, 2024 | proactiveinvestors.comNanoViricides drug asset shows ‘superior antiviral effects' against Influenza AMay 6, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza AApril 30, 2024 | proactiveinvestors.comNanoViricides completes Phase 1 trial of lead asset NV-387February 26, 2024 | benzinga.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsFebruary 15, 2024 | proactiveinvestors.comNanoViricides boosts liquidity measures and manufacturing capacity to support clinical trialsFebruary 15, 2024 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the HorizonFebruary 1, 2024 | benzinga.comA New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?February 1, 2024 | finance.yahoo.comClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as AntibioticsJanuary 29, 2024 | proactiveinvestors.comNanoViricides successfully concludes first-in-human studyJanuary 29, 2024 | proactiveinvestors.comNanoViricides makes progress as it completes dosing in Phase 1a COVID studyJanuary 29, 2024 | finance.yahoo.comSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events FoundJanuary 8, 2024 | benzinga.comNanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024January 7, 2024 | morningstar.comNanoviricides Inc NNVCJanuary 4, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San FransiscoDecember 1, 2023 | benzinga.comNanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387November 28, 2023 | proactiveinvestors.comNanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drugNovember 28, 2023 | finance.yahoo.comThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricidesNovember 15, 2023 | proactiveinvestors.comNanoViricides continues to progress antiviral drug candidate...November 15, 2023 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional ApplicationsOctober 17, 2023 | proactiveinvestors.comNanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirusOctober 16, 2023 | finance.yahoo.comNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSVOctober 12, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ETSeptember 5, 2023 | finance.yahoo.comNNVC: NanoViricides Begins Clinical Trial of NV-CoV-2August 31, 2023 | finance.yahoo.comNanoViricides progressing well with new Covid studyAugust 29, 2023 | msn.com$NNVC Reports Their Broad-Spectrum Antiviral Drugs Human Clinical Trial Is Progressing SuccessfullyAugust 23, 2023 | proactiveinvestors.comNanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against virusesAugust 21, 2023 | finance.yahoo.comThe Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricidesJuly 18, 2023 | benzinga.comSARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?July 13, 2023 | finance.yahoo.comNanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research AnalystJuly 11, 2023 | marketwatch.comNanoViricides Shares Surge on NV-387 Showing in RSV >NNVCJuly 11, 2023 | benzinga.comWhy Are NanoViricides Shares Gaining Today Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NNVC Media Mentions By Week NNVC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NNVC News Sentiment▼0.000.79▲Average Medical News Sentiment NNVC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NNVC Articles This Week▼21▲NNVC Articles Average Week Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Acasti Pharma News Enlivex Therapeutics News Oncternal Therapeutics News BioVie News TherapeuticsMD News Lisata Therapeutics News Aprea Therapeutics News JanOne News Aptorum Group News Spruce Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NNVC) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
